Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).

A legfontosabb adatok

Ki végzi
Medtronic Neurovascular Clinical Affairs
Hol
Albany, Boston, Buffalo, Camden, Charlotte, Chicago, Cleveland, Englewood, Greenville, Indianapolis, Iowa City, Jacksonville, Los Angeles, Memphis, Morgantown, New Haven, New York, Oklahoma City, Park Ridge, Philadelphia, Pittsburgh, Salt Lake City, Stony Brook és Tampa (Egyesült Államok)Mind a 25 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
300 fő, tervezett
Kezdés
2024. ápr. 16.
Várható befejezés
2032. febr.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Artisse™ Intrasaccular Device
A regiszteradat frissítve
2026. október 9.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with one wide-neck brain aneurysm at a vessel branch point, burst or not burst, to be treated with the Artisse™ Intrasaccular Device.

Életkor
18-75 years
Nem
All sexes
A betegség stádiuma
A single saccular (sac-shaped) brain aneurysm at a branching point, needing treatment. Neck size ≥ 4 mm and/or dome-to-neck ratio of ≥ 1 and < 2. If it burst within the last 30-days, Hunt and Hess Grade I or II and stable. At least one risk factor for rupture. The doctor has already chosen treatment through the blood vessels.
Korábbi kezelés
The target aneurysm must not have been treated before with other devices, such as coils. Another aneurysm treated before must have been stable for the past 90 days.

A részvétel fő kizáró okai

  • Planned need for another implant device besides the Artisse™ device, or a stent in the parent artery
  • Disability score mRS > 2 before the procedure or before the rupture
  • Bleeding in the brain from another source within 90 days
  • Pregnancy, or plans to become pregnant during the 1 year follow-up
  • Blood thinners that cannot be stopped for at least 7 days after the procedure, or kidney failure blocking angiography (unless on dialysis)

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject or subject's Legally Authorized Representative (LAR) has provided written informed consent using the Institutional Review Board/Ethics Committee (IRB/EC) approved Informed Consent Form (ICF). Health Insurance Portability and Accountability Act (HIPAA)/data protection authorization has been provided and signed by the subject or subject's LAR
  • Subject is 18-75 years of age at the time of consent
  • Subject has a single unruptured or ruptured IA requiring treatment. If the patient has an additional IA, the additional IA must not be deemed to require treatment within 1-year of the index procedure
  • The target aneurysm must have the following characteristics:; Saccular morphology; Located at a bifurcation in the anterior or posterior circulation; Aneurysm Width appropriate for treatment with the Artisse™ Intrasaccular Device for device sizingper the Instructions for Use; Wide-necked, defined as neck size ≥ 4 mm and/or a dome-to-neck ratio of ≥ 1 and < 2
  • If the target aneurysm was acutely ruptured, subject must be neurologically stable with Hunt and Hess Grade of I or II; Ruptured IA is defined as showing evidence of SAH attributed to the target aneurysm within the last 30-days (using computed tomography (CT), magnetic resonance imaging (MRI), or lumbar puncture (LP).)
  • Subject is able to comply with all aspects of the Clinical Investigation Plan (CIP) requirements (e.g., screening, evaluation, treatment, and the post-procedure follow-up schedule)
  • Subject meets one or more risk factors for IA rupture, such as age, hypertension, cigarette smoking, use of sympathomimetic drugs, Japanese or Finnish ancestry, history of prior aneurysmal subarachnoid hemorrhage (aSAH), familial intracranial aneurysms or SAH, clinical or radiological mass effect, reduced quality of life due to fear of rupture, IA size, location, and morphology, documented growth of IA on serial imaging (or enhanced aneurysm walls on contrast), presence of multiple IAs, and presence of concurrent pathology
  • Treating physician has already selected the subject for endovascular treatment of the target aneurysm after considering risk-benefit of clipping vs endovascular treatment
  • If the subject has an additional IA that was treated previously, the additional IA must have been clinically stable in the past 90 days (i.e. without ongoing adverse events related to the previous treatment)

Ki nem vehet részt

  • During treatment planning, it is determined that subject may need an adjunctive implant device in addition to the Artisse™ Intrasaccular Device. (Subjects who need unplanned adjunctive implant devices are not excluded.)
  • Subject's target aneurysm was previously treated with other devices/implants (e.g., coils) or parent artery has a stent or other obstruction that could interfere with the correct placement of the Artisse™ Intrasaccular Device
  • Subject has anatomy or physiology considered unsuitable (e.g., vessel anomaly or disease) for endovascular treatment with the Artisse™ Intrasaccular Device by the treating physician
  • Subject has a mRS score > 2 (i.e., mRS scores of 3 to 5) prior to procedure (in case of unruptured IA) or prior to rupture (in case of ruptured IA)
  • Subject is enrolled in another device or drug study in which participation could confound study results
  • Subject has a known active systemic bacterial infection
  • Subject has an SAH from a non-target aneurysm or any other intracranial hemorrhage within 90 days
  • The treating physician determines that the health of the subject or the validity of the study outcomes (e.g., high risk of neurologic events, conditions that may increase the chance of stroke) may be compromised by the subject's enrollment
  • Subject has a known hypersensitivity, which cannot be medically treated, to any component of the study device, procedural materials, or medications commonly used during the procedure
  • Subject has acute or chronic renal failure (unless on dialysis) that would prevent them from undergoing digital subtraction angiography (DSA)
  • Subject has a life expectancy of less than 5 years due to an illness or condition other than the index IA
  • Subject, of child-bearing potential, is pregnant (confirmed with a positive pregnancy test) or plans to become pregnant during the 1 year follow up period after the index procedure
  • Subject is taking anticoagulants (e.g., warfarin) that cannot be discontinued for a minimum of 7 days post-procedure or have a known blood dyscrasia, coagulopathy, or hemoglobinopathy

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 75 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Albany Medical CenterAlbany, Egyesült ÁllamokContact: Alexandra Paul, MDRésztvevőt keres
  • Massachusetts General HospitalBoston, Egyesült ÁllamokContact: Shayna HollanderRésztvevőt keres
  • Buffalo General Medical CenterBuffalo, Egyesült ÁllamokContact: Adnan Siddiqui, MDRésztvevőt keres
  • Cooper University HealthCamden, Egyesült ÁllamokContact: Thuy Van CaoRésztvevőt keres
  • Novant Health Brain and Spine SurgeryCharlotte, Egyesült ÁllamokContact: Ziad Hage, MDRésztvevőt keres
  • University of ChicagoChicago, Egyesült ÁllamokContact: Khalid TradRésztvevőt keres
  • Cleveland Clinic FoundationCleveland, Egyesült ÁllamokContact: Heidi PoppendeckRésztvevőt keres
  • Swedish Medical CenterEnglewood, Egyesült ÁllamokContact: Ashley ThompsonRésztvevőt keres
  • Prisma HealthGreenville, Egyesült ÁllamokContact: Mohammad Chaudry, MDRésztvevőt keres
  • Ascension Saint Vincent Hospital - IndianapolisIndianapolis, Egyesült ÁllamokContact: Luke WatkinsRésztvevőt keres
  • University of Iowa Hospitals and ClinicsIowa City, Egyesült ÁllamokContact: Heena OlaldeRésztvevőt keres
  • Baptist Medical Center JacksonvilleJacksonville, Egyesült ÁllamokContact: Smitha Gubbi, MDRésztvevőt keres
  • USC Keck School of MedicineLos Angeles, Egyesült ÁllamokContact: Kelly HuRésztvevőt keres
  • Semmes Murphy ClinicMemphis, Egyesült ÁllamokContact: Wendell BarnettRésztvevőt keres
  • West Virginia UniversityMorgantown, Egyesült ÁllamokContact: Jennifer DomicoRésztvevőt keres
  • Yale New Haven HospitalNew Haven, Egyesült ÁllamokContact: Lindsey FraczkiewiczRésztvevőt keres
  • The Mount Sinai HospitalNew York, Egyesült ÁllamokContact: Johanna Fifi, MDRésztvevőt keres
  • Oklahoma University Medical CenterOklahoma City, Egyesült ÁllamokContact: Katarzyna Zyla-JacksonRésztvevőt keres
  • Advocate Lutheran General HospitalPark Ridge, Egyesült ÁllamokContact: Victor ArroyoRésztvevőt keres
  • Hospital of the University of PennsylvaniaPhiladelphia, Egyesült ÁllamokContact: Christopher BoivinRésztvevőt keres
  • Thomas Jefferson University HospitalPhiladelphia, Egyesült ÁllamokContact: Nico AgostiRésztvevőt keres
  • UPMC PresbyterianPittsburgh, Egyesült ÁllamokContact: Lauren PuccioRésztvevőt keres
  • University of Utah HospitalSalt Lake City, Egyesült ÁllamokContact: Ramesh Grandhi, MDRésztvevőt keres
  • Stony Brook University HospitalStony Brook, Egyesült ÁllamokContact: Marlene BaumeisterRésztvevőt keres
  • Tampa General HospitalTampa, Egyesült ÁllamokContact: Muni Sai BachalakuriRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to assess the safety and effectiveness of the Artisse™ Intrasaccular Device in the treatment of unruptured and ruptured wide-neck bifurcating intracranial aneurysms.

A vizsgálat csoportja

  • Artisse™ Intrasaccular DeviceA vizsgált kezelés

    Study subjects with an unruptured or ruptured wide-neck bifurcating intracranial aneurysm will be treated by endovascular implantation of the Artisse™ Intrasaccular Device.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Artisse™ Intrasaccular Device IDE
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT02998229: ki vehet részt
A regiszteradat frissítve
2026. október 9.